Vestal Point Capital LP Acquires Shares of 20,000 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vestal Point Capital LP purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, HoldingsChannel.com reports. The firm purchased 20,000 shares of the biopharmaceutical company’s stock, valued at approximately $14,247,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $28,000. Rakuten Securities Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the period. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC lifted its stake in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 39 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $594.32 on Monday. The company has a market cap of $64.17 billion, a P/E ratio of 15.53, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business’s 50 day moving average price is $599.96 and its 200-day moving average price is $681.90. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $520.50 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The firm had revenue of $3.03 billion during the quarter, compared to analysts’ expectations of $3.40 billion. During the same quarter in the prior year, the company posted $9.55 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was down 3.7% compared to the same quarter last year. Sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.96%.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on REGN. StockNews.com lowered Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 1st. Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a report on Tuesday, February 4th. BMO Capital Markets reduced their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Finally, Bank of America dropped their price objective on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $890.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.